BASIS-TECHNOLOGIES
28.4.2016 14:03:46 CEST | Business Wire | Press release
Basis Technologies today announces the introduction of Consolidator, a new addition to its extensive range of automation tools. Consolidator performs the technical analysis and merge of SAP ECC systems, including those running on HANA, with minimal user intervention. Automation reduces the risk and cost of the overall process, allowing more businesses to realize the benefits of SAP system consolidation.
A time of change
Sixty-four percent of IT and marketing executives recently surveyed by Gartner said that they expect to transform into a digital business by the end of 20171 .
In such a dynamic, disruptive environment, business initiatives like digital transformation are becoming commonplace. A shift to cloud-based Enterprise Resource Planning (ERP) solutions, including S/4HANA from SAP, is also underway, and M&A activity continues to gather pace. Meanwhile, potentially huge opportunities lurk inside inefficient SAP system landscapes built up over decades of acquisitions and reorganizations.
All of these factors are combining to generate an ever-increasing level of demand for SAP system consolidation projects.
A new way to unlock value
To date, a limited number of tools have been available to support system consolidation. This has resulted in processes which feature an unavoidably high level of manual effort, with the corresponding business risk that such methods naturally bring.
Consolidator offers the chance to automate a critical - and labor-intensive - portion of the consolidation process: the technical merge. Risk and necessary resource inputs are dramatically reduced, enabling businesses to unlock value, focus on innovation, reduce cost of ownership and prepare for a new generation of enterprise solutions.
"Businesses should give more thought to optimization of the SAP systems that enable great customer experiences. Too much cash is being wasted on simply maintaining existing processes and stabilizing legacy infrastructure." said Martin Metcalf, Chief Executive Officer of Basis Technologies. "There is just not enough focus placed on unlocking the latent value within these assets through the use of automation technologies such as Consolidator"
To learn more about Consolidator, visit www.basistechnologies.com/consolidator
About Basis Technologies
Basis Technologies have delivered innovative software solutions for SAP for almost 20 years. We focus on automation tools that enable continuous delivery, helping our customers to keep pace with theirs. Our products support the adoption of methodologies such as Agile and DevOps in an SAP environment, and our client list includes a selection of major multinational companies such as BP, Unilever and Ralph Lauren.
To find out more, visit www.basistechnologies.com .
####
1. Navigate Your Way to Digital Business Transformation With These Resources, Don Scheibenreif, VP Distinguished Analyst, Gartner (August 2015)
2. Consolidator does not support the analysis or merge of transactional or master data. Other tools may be required.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160428005020/en/
Contact:
Basis Technologies
Peter Yabsley
Head of Product Marketing
+44
7867 335 310
peter.yabsley@basistechnologies.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom